Avalo Therapeutics
AVTX
9 hedge funds and large institutions have $2.37M invested in Avalo Therapeutics in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
383% more capital invested
Capital invested by funds: $491K → $2.37M (+$1.88M)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
29% more funds holding
Funds holding: 7 → 9 (+2)
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.92M |
| 2 |
Bank of New York Mellon
New York
|
+$14.7K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$9.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$9K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$1.63K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $1.94M | +$1.92M | +1,175 | New |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $341K | – | – | – |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $34K | +$1.63K | +1 | +5% |
|
|
VKH
4
Virtu KCG Holdings
New York
| $23K | -$1.63K | -1 | -7% |
|
|
5
Bank of New York Mellon
New York
| $14K | +$14.7K | +9 | New |
|
|
6
Citadel Advisors
Miami,
Florida
| $10K | +$9.8K | +6 | New |
|
7
Commonwealth Equity Services
Waltham,
Massachusetts
| $7K | – | – | – |
|
8
BlackRock
New York
| $2K | – | – | – |
|
|
TWA
9
TCI Wealth Advisors
Tucson,
Arizona
| $2K | – | – | – |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$9K | -5 | Closed |
|
AVTX Hedge Fund Activity: Q2 2017 in Review
9 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2017, worth a combined $2.37M — up 383% from $491K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new AVTX positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.92M. The largest seller was UBS Group, exiting entirely with an estimated $9K sold.
- 9 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2017, up from 7 in Q1 2017.
- Funds reported $2.37M of Avalo Therapeutics stock for Q2 2017, up 383% quarter-over-quarter.
- 3 funds opened new Avalo Therapeutics positions in Q2 2017 and 1 closed out, a net change of +2 holders.
- The largest Avalo Therapeutics buyer in Q2 2017 was Armistice Capital, an estimated $1.92M added.
- The largest Avalo Therapeutics seller in Q2 2017 was UBS Group, an estimated $9K sold.
Based on aggregated 13F filings for Q2 2017.